Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 5/2000

01-10-2000 | Review

Estrogen receptor transcription and transactivation Basic aspects of estrogen action

Authors: Stefan Nilsson, Jan-Åke Gustafsson

Published in: Breast Cancer Research | Issue 5/2000

Login to get access

Abstract

Estrogen signaling has turned out to be much more complex and exciting than previously thought; the paradigm shift in our understanding of estrogen action came in 1996, when the presence of a new estrogen receptor (ER), ERβ, was reported. An intricate interplay between the classical ERα and the novel ERβ is of paramount importance for the final biological effect of estrogen in different target cells.
Literature
1.
Jensen EV, Jacobsen HI: Basic guides to the mechanism of estrogen action. Recent Prog Horm Res. 1962, 18: 387-414.
2.
Green S, Walter P, Kumar V, et al: Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature. 1986, 320: 134-139.PubMedCrossRef
3.
Greene GL, Gilna P, Waterfield M, et al: Sequence and expression of human estrogen receptor complementary DNA. Science . 1986, 231: 1150-1154.PubMedCrossRef
4.
Kuiper GGJM, Enmark E, Pelto-Huikko M, et al: Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA. 1996, 93: 5925-5930. 10.1073/pnas.93.12.5925. This paper initiated a paradigm shift in the understanding of estrogen action, and was the first report on the second estrogen receptor ERβ.PubMedPubMedCentralCrossRef
5.
Mosselman S, Polman J, Dijkema R: ERβ: identification and characterization of a novel human estrogen receptor. FEBS Lett. 1996, 392: 49-53. 10.1016/0014-5793(96)00782-X.PubMedCrossRef
6.
Enmark E, Pelto-Huikko M, Grandien K, et al: Human estrogen receptor β - gene structure, chromosomal localisation and expression pattern. J Clin Endocrinol Met. 1997, 82: 4258-4265. 10.1210/jc.82.12.4258.
7.
Tremblay GB, Tremblay A, Copeland NG, et al: Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor β. Mol Endocrinol. 1997, 11: 352-365. 10.1210/me.11.3.353.
8.
Petersen DN, Tkalcevic GT, Koza-Taylor PH, et al: Identification of estrogen receptor β2, a functional variant of estrogen receptor β expressed in normal rat tissues. Endocrinology. 1998, 139: 1082-1092. 10.1210/en.139.3.1082.PubMed
9.
Hanstein B, Liu H, Yancisin M, Brown M: Functional analysis of a novel estrogen receptor-β isoform. Mol Endocrinol. 1999, 13: 129-137. 10.1210/me.13.1.129.PubMed
10.
Ogawa S, Inoue S, Watanabe T, et al: Molecular cloning and characterization of human estrogen receptor βcx: a potential inhibitor of estrogen action in human. Nucleic Acids Res . 1998, 26: 3505-3512. 10.1093/nar/26.15.3505.PubMedPubMedCentralCrossRef
11.
Fuqua SAW, Chamness GC, McGuire WL: Estrogen receptor mutations in breast cancer. J Cell Biochem. 1993, 51: 135-139.PubMedCrossRef
12.
Friend KE, Ang LW, Shupnik MA: Estrogen regulates the expression of several different estrogen receptor mRNA isoforms in rat pituitary. Proc Natl Acad Sci USA. 1995, 92: 4367-4371.PubMedPubMedCentralCrossRef
13.
Zhang QX, Hilsenbeck SG, Fuqua SA, et al: Multiple splicing variants of the estrogen receptor are present in individual human breast tumors. J Steroid Biochem Mol Biol. 1996, 59: 251-260. 10.1016/S0960-0760(96)00120-3.PubMedCrossRef
14.
Friend KE, Resnick EM, Ang LW, et al: Specific modulation of estrogen receptor mRNA isoforms in rat pituitary throughout the estrous cycle and in response to steroid hormones. Mol Cell Endocrinol. 1997, 131: 147-155. 10.1016/S0303-7207(97)00098-1.PubMedCrossRef
15.
Murphy LC, Dotzlaw H, Leygue E, et al: Estrogen receptor variants and mutations. J Steroid Biochem Mol Biol. 1997, 62: 363-372. 10.1016/S0960-0760(97)00084-8.PubMedCrossRef
16.
Taylor JA, Lewis KJ, Lubahn DB: Estrogen receptor mutations. Mol Cell Endocrinol. 1998, 145: 61-66. 10.1016/S0303-7207(98)00170-1.PubMedCrossRef
17.
18.
Tsai MJ, O'Malley BW: Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem. 1994, 63: 451-486. 10.1146/annurev.bi.63.070194.002315.PubMedCrossRef
19.
Gronemeyer H, Laudet V: Transcription factors 3: nuclear receptors. Protein Profile. 1995, 2: 1167-1322.
20.
Mangelsdorf DJ, Thummel C, Beato M, et al: The nuclear receptor superfamily: the second decade. Cell. 1995, 83: 835-839. 10.1016/0092-8674(95)90199-X.PubMedCrossRef
21.
Katzenellenbogen JA, Katzenellenbogen BS: Nuclear hormone receptors: ligand-activated regulators of transcription and diverse cell responses. Chem Biol. 1996, 3: 529-536. 10.1016/S1074-5521(96)90143-X.PubMedCrossRef
22.
Giguère V: Orphan nuclear receptors: from gene to function. Endocrine Rev. 1999, 20: 689-725. 10.1210/er.20.5.689.
23.
Beekman JM, Allan GF, Tsai SY, et al: Transcriptional activation by the estrogen receptor requires a conformational change in the ligand binding domain. Mol Endocrinol. 1993, 7: 1266-1274. 10.1210/me.7.10.1266.PubMed
24.
McDonnell DP, Clemm DL, Hermann T, et al: Analysis of estrogen receptor function in vitro reveals three distinct classes of anti-estrogens. Mol Endocrinol. 1995, 9: 659-669. 10.1210/me.9.6.659.PubMed
25.
Katzenellenbogen J, O'Malley BW, Katzenellenbogen BS: Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. Mol Endocrinol. 1996, 10: 119-131. 10.1210/me.10.2.119.PubMed
26.
Shibata H, Spencer TE, Onate SA, et al: Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action. Recent Prog Horm Res. 1996, 52: 141-165.
27.
Tora L, White J, Brou C, et al: The human estrogen receptor has two independent nonacidic activation functions. Cell . 1989, 59: 477-487.PubMedCrossRef
28.
Berry M, Metzger D, Chambon P: Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J. 1990, 9: 2811-2818.PubMedPubMedCentral
29.
Kraus WL, McInerney EM, Katzenellenbogen BS: Ligand-dependent transcriptionally productive association of the amino- and carboxy-terminal regions of a steroid hormone nuclear receptor. Proc Natl Acad Sci USA. 1995, 92: 12314-12318.PubMedPubMedCentralCrossRef
30.
McInerney EM, Katzenellenbogen BS: Different regions in activation function-1 of the human estrogen receptor required for antiestrogen- and estradiol-dependent transcription activation. J Biol Chem. 1996, 271: 24172-24178. 10.1074/jbc.271.39.24172.PubMedCrossRef
31.
Barkhem T, Carlsson B, Nilsson Y, et al: Differential response of estrogen receptor α and estrogen receptor β to partial estrogen agonists/antagonists. Mol Pharmacol . 1998, 54: 105-112., This is a very important paper demonstrating the differences in ligand binding specificities between HERa and ERβPubMed
32.
McInerney EM, Weis KE, Sun J, et al: Transcription activation by the human estrogen receptor subtype β (ERβ) studied with ERβ and ERα receptor chimeras. Endocrinology. 1998, 139: 4513-4522. 10.1210/en.139.11.4513.PubMed
33.
Danielian PS, White R, Lees JA, et al: Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. EMBO J. 1992, 11: 1025-1033.PubMedPubMedCentral
34.
Henttu PMA, Kalkhoven E, Parker MG: AF-2 activity and recruitment of steroid receptor coactivator 1 to the estrogen receptor depend on a lysine residue conserved in nuclear receptors. Mol Cell Biol. 1997, 17: 1832-1839.PubMedPubMedCentralCrossRef
35.
36.
Feng W, Ribeiro RC, Wagner RL, et al: Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science. 1998, 280: 1747-1749. 10.1126/science.280.5370.1747.PubMedCrossRef
37.
38.
Brzozowski AM, Pike ACW, Dauter Z, et al: Molecular basis of agonism and antagonism in the estrogen receptor. Nature . 1997, 389: 753-758. 10.1038/39645., This is the first of two papers [38,39] revealing clear pictures of the LBD of estrogen receptors with their ligands. This is a much quoted and uniquely original study, demonstrating for the first time how the structure of the LBD of nuclear receptors (in this case, estrogen receptor a) is altered upon agonist/antagonist bindingPubMedCrossRef
39.
Pike ACW, Brzozowski AM, Hubbard RE, et al: Structure of the ligand-binding domain of oestrogen receptor β in the presence of a partial agonist and a full antagonist. The EMBO J . 1999, 18: 4608-4618. 10.1093/emboj/18.17.4608.PubMedCrossRef
40.
Paige LA, Christensen DJ, Gron H, et al: Estrogen receptor (ER) modulators each induce distinct conformational changes in ERα and ERβ. Proc Natl Acad Sci USA . 1999, 96: 3999-4004. 10.1073/pnas.96.7.3999.PubMedPubMedCentralCrossRef
41.
Paech K, Webb P, Kuiper GGJM, et al: Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science. 1997, 277: 1508-1510. 10.1126/science.277.5331.1508., This is an extremely important paper demonstrating, for the first time, that ERα and ERβ can have opposite effects in modulation of expression of genesPubMedCrossRef
42.
Conte FA, Grumbach MM, Ito Y, et al: A syndrome of female pseudohermaphrodism, hypergonadotropic hypogonadism, and multicystic ovaries associated with missense mutations in the gene encoding aromatase (P450 arom). J Clin Endocrinol Metab. 1994, 78: 1287-1292. 10.1210/jc.78.6.1287.PubMed
43.
Morishima A, Grumbach MM, Simpson ER, et al: Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab. 1995, 80: 3689-3698. 10.1210/jc.80.12.3689.PubMed
44.
MacGillivray MH, Morishima A, Conte F, et al: Pedriatic endocrinology update: an overview. The essential roles of estrogens in pubertal growth, epiphyseal fusion and bone turnover: lessons from mutations in the genes for aromatase and the estrogen receptor. Horm Res . 1998, 49 (suppl 1): 2-8. 10.1159/000053061.CrossRef
45.
Masood S: Estrogen and progesterone receptors in cytology: a comprehensive review. Diagn Cytopathol. 1992, 8: 475-491.PubMedCrossRef
46.
Jordan VC: Molecular mechanisms of antiestrogen action in breast cancer. Breast Cancer Res Treat. 1994, 31: 41-52.PubMedCrossRef
47.
Osborne CK, Elledge RM, Fuqua SA: Estrogen receptors in breast cancer therapy. Sci Am. 1996, 32-41.
48.
Dotzlaw H, Leygue E, Watson PH, et al: Expression of estrogen receptor-β in human breast tumors. J Clin Endocrinol Metab. 1997, 82: 2371-2374. 10.1210/jc.82.7.2371.PubMed
49.
Leygue E, Dotzlaw H, Watson PH, et al: Expression of estrogen receptor β1, β2, and β5 messenger RNAs in human breast tissue. Cancer Res. 1999, 59: 1175-1179.PubMed
50.
Sasano H, Suzuki T, Matsuzaki Y, et al: Messenger ribonucleic acid in situ hybridization analysis of estrogen receptors α and β in human breast carcinoma. J Clin Endocrinol Metab. 1999, 84: 781-785. 10.1210/jc.84.2.781.PubMed
51.
Saji S, Jensen EV, Nilsson S, et al: Estrogen receptors α and β in the rodent mammary gland. Proc Natl Acad Sci USA. 2000, 97: 337-342. 10.1073/pnas.97.1.337., This study reveals, for the first time, the cellular expression and regulation of ERa and ERα in the rodent breast. The study reveals that epithelial cells that divide in the breast have neither estrogen receptorPubMedPubMedCentralCrossRef
52.
Dotzlaw H, Leygue E, Watson PH, et al: Estrogen receptor-β messenger RNA expression in human breast tumor biopsies: relationship to steroid receptor status and regulation by progestins. Cancer Res. 1999, 59: 529-532.PubMed
53.
Speirs V, Parkes AT, Kerin MJ, et al: Coexpression of estrogen receptor-α and -β: poor prognostic factors in human breast cancer?. Cancer Res. 1999, 59: 525-528., This paper should be read because it formulates an important question for which there are no answers at present because of the paucity of informationPubMed
54.
Lichtman R: Perimenopausal and postmenopausal hormone replacement therapy. Part 1. An update of the literature on benefits and risks. Nurse Midwifery. 1996, 41: 3-28. 10.1016/0091-2182(95)00082-8.CrossRef
55.
Lichtman R: Perimenopausal and postmenopausal hormone replacement therapy. Part 2. Hormonal regimens and complementary and alternative therapies. Nurse Midwifery. 1996, 41: 195-210. 10.1016/0091-2182(96)00020-1.CrossRef
56.
Saunders PTK, Maguire SM, Gaughan J, et al: Expression of oestrogen receptor (ERβ) in multiple rat tissues visualised by immunohistochemistry. J Endocrinol. 1997, 154: R13-R16.PubMedCrossRef
57.
Mäkelä S, Strauss L, Kuiper G, et al: Differential expression of estrogen receptors α and β in adult rat accessory sex glands and lower urinary tract. Mol Cell Endocrinol (in press).
58.
Chang WY, Prins GS: Estrogen receptor-β: implications for the prostate gland. Prostate. 1999, 40: 115-124. 10.1002/(SICI)1097-0045(19990701)40:2<115::AID-PROS7>3.0.CO;2-3., This paper must be read because it is clear that ERβ, and therefore estrogens, have a role in regulation of prostatic growth and developmentPubMedCrossRef
59.
Krege JH, Hodgin JB, Couse JF, et al: Generation and reproductive phenotypes of mice lacking estrogen receptor β . Proc Natl Acad Sci USA. 1998, 95: 15677-15682. 10.1073/pnas.95.26.15677.PubMedPubMedCentralCrossRef
60.
Lindsay R, Hart DM, Aitken JM, et al: Long-term prevention of post-menopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment. Lancet. 1976, 1: 1038-1041. 10.1016/S0140-6736(76)92217-0.PubMedCrossRef
61.
Christiansen C: Hormonal prevention and treatment of osteoporosis -- state of the art 1990. J Steroid Biochem Mol Biol . 1990, 37: 447-449. 10.1016/0960-0760(90)90496-8.PubMedCrossRef
62.
Cauley JA, Seeley DG, Ensrud K, et al: Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med. 1995, 122: 9-16.PubMedCrossRef
63.
Spelsberg TC, Subramaniam M, Riggs L, et al: The actions and interactions of sex steroids and growth factors/cytokines on the skeleton. Mol Endocrinol. 1999, 13: 819-828. 10.1210/me.13.6.819.PubMedCrossRef
64.
Komm BS, Terpening CM, Benz DJ, et al: Estrogen binding receptor mRNA and biological response in osteoblast-like osteosarcoma cells. Science. 1988, 241: 81-83.PubMedCrossRef
65.
Eriksen EF, Colvard DS, Berg NJ, et al: Evidence of estrogen receptors in normal human osteoblast-like cells. Science . 1988, 241: 84-86.PubMedCrossRef
66.
Hofbauer LC, Khosla S, Dunstan CR, et al: Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology. 1999, 140: 4367-4370. 10.1210/en.140.9.4367.PubMed
67.
Oursler MJ, Pederson L, Fitzpatrick L, et al: Human giant cell tumors of the bone (osteoclastomas) are estrogen target cells. Proc Natl Acad Sci USA. 1994, 91: 5227-5231.PubMedPubMedCentralCrossRef
68.
Onoe Y, Miyaura C, Ohta H, Nozawa S, Suda T: Expression of estrogen receptor β in rat bone. Endocrinology . 1997, 138: 4509-4512. 10.1210/en.138.10.4509.PubMed
69.
Arts J, Kuiper GGJM, Janssen JM, et al: Differential expression of estrogen receptors α and β mRNA during differentiation of human osteoblast SV-HFO cells. Endocrinology. 1997, 138: 5067-5070. 10.1210/en.138.11.5067.PubMed
70.
Stampfer MJ, Colditz GA: Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991, 20: 47-63. 10.1016/0091-7435(91)90006-P.PubMedCrossRef
71.
Nabulsi AA, Folsom AR, White A, et al: Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med. 1993, 328: 1069-1075. 10.1056/NEJM199304153281501.PubMedCrossRef
72.
Grodstein F, Stampfer MJ, Colditz GA, et al: Postmenopausal hormone therapy and mortality. N Engl J Med . 1997, 336: 1769-1775. 10.1056/NEJM199706193362501.PubMedCrossRef
73.
Nathan L, Chaudhuri G: Estrogens and atherosclerosis. Annu Rev Pharmacol Toxicol. 1997, 37: 477-515. 10.1146/annurev.pharmtox.37.1.477.PubMedCrossRef
74.
Mendelsohn ME, Karas RH: The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1997, 340: 1801-1811. 10.1056/NEJM199906103402306.
75.
Kim-Schulze S, McGowan KA, Hubchak SC, et al: Expression of an estrogen receptor by human coronary artery and umbilical vein endothelial cells. Circulation. 1996, 94: 1402-1407.PubMedCrossRef
76.
Venkov CD, Rankin AB, Vaughan DE: Identification of authentic estrogen receptor in cultured endothelial cells: a potential mechanism for steroid hormone regulation of endothelial function. Circulation . 1996, 94: 727-733.PubMedCrossRef
77.
Karas RH, Patterson BL, Mendelsohn ME: Human vascular smooth muscle cells contain functional estrogen receptor. Circulation. 1994, 89: 1943-1950.PubMedCrossRef
78.
Register TC, Adams MR: Coronary artery and cultured aortic smooth muscle cells express mRNA for both the classical estrogen receptor and the newly described estrogen receptor β. J Steroid Biochem Mol Biol. 1998, 64: 187-191. 10.1016/S0960-0760(97)00155-6.PubMedCrossRef
79.
Lindner V, Kim SK, Karas RH, et al: Increased expression of estrogen receptor-β mRNA in male blood vessels after vascular injury. Circulation Res. 1998, 83: 224-229.PubMedCrossRef
80.
Grohé C, Kahlert S, Lobbert K, et al: Cardiac myocytes and fibroblasts contain functional estrogen receptors. FEBS Lett . 1997, 416: 107-112. 10.1016/S0014-5793(97)01179-4.PubMedCrossRef
81.
White MM, Zamudio S, Stevens T, et al: Estrogen, progesterone, and vascular reactivity: potential cellular mechanisms. Endocr Rev. 1995, 16: 739-751. 10.1210/er.16.6.739.PubMed
82.
Foegh ML, Ramwell PW: Cardiovascular effects of estrogen: implications of the discovery of the estrogen receptor subtype β. Curr Opin Nephr Hypertens. 1998, 7: 83-89. 10.1097/00041552-199801000-00014.
83.
Valverde MA, Rojas P, Amigo J, et al: Acute activation of Maxi-k channels (hSlo) by estradiol binding to the β subunit. Science. 1999, 285: 1929-1931. 10.1126/science.285.5435.1929.PubMedCrossRef
84.
Farhat MY, Abi-Younes S, Ramwell PW: Non-genomic effects of estrogen and the vessel wall. Biochem Pharmacol. 1996, 51: 571-576. 10.1016/S0006-2952(95)02159-0.PubMedCrossRef
85.
Kauser K, Rubanyi GM: Potential cellular signaling mechanisms mediating upregulation of endothelial nitric oxide production by estrogen. J Vascular Res. 1997, 34: 229-236.CrossRef
86.
Nuedling S, Kahlert S, Loebbert K, et al: Differential effects of 17 β-estradiol on mitogen-activated protein kinase pathways in rat car-diomyocytes. FEBS Lett. 1999, 454: 271-276. 10.1016/S0014-5793(99)00816-9.PubMedCrossRef
87.
Chen Z, Yuhanna IS, Galcheva-Gargova Z, et al: Estrogen receptor α mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest. 1999, 103: 401-406.PubMedPubMedCentralCrossRef
88.
89.
Farhat MY, Lavigne MC, Ramwell PW: The vascular protective effects of estrogen. FASEB J. 1996, 10: 615-624.PubMed
90.
Grohé C, Kahlert S, Lobbert K, et al: Expression of oestrogen receptor α and β in rat heart: role of local oestrogen synthesis. J Endocrinol. 1998, 156: R1-R7.PubMedCrossRef
91.
Mikkola T, Viinikka L, Ylikorkala O: Estrogen and postmenopausal estrogen/progestin therapy: effect on endothelium-dependent prostacyclin, nitric oxide and endothelin-1 production. Eur J Obstet Gynecol Reprod Biol. 1998, 79: 75-82. 10.1016/S0301-2115(98)00050-5.PubMedCrossRef
92.
93.
Pinkerton JV, Santen R: Alternatives to the use of estrogen in post-menopausal women. Endocrine Rev. 1999, 20: 308-320. 10.1210/er.20.3.308.CrossRef
94.
Nickenig G, Baumer AT, Grohe C, et al: Estrogen modulates AT1 receptor gene expression in vitro and in vivo. Circulation. 1998, 97: 2197-2201.PubMedCrossRef
95.
Foegh ML, Khirabadi BS, Nakanishi T, et al: Estradiol protects against experimental cardiac transplant atherosclerosis. Transplant Proc. 1987, 19 (suppl 5): 90-95.
96.
Foegh ML, Asotra S, Howell MH, et al: Estradiol inhibition of arterial neointimal hyperplasia after balloon injury. J Vasc Surg. 1994, 19: 722-726.PubMedCrossRef
97.
Akishita M, Ouchi Y, Miyoshi H, et al: Estrogen inhibits cuff-induced intimal thickening of rat femoral artery: effects on migration and proliferation of vascular smooth muscle cells. Atherosclerosis. 1997, 130: 1-10. 10.1016/S0021-9150(96)06023-6.PubMedCrossRef
98.
Scheuer J, Malhotra A, Schaible TF, et al: Effects of gonadectomy and hormonal replacement on rat hearts. Circ Res. 1987, 61: 12-19.PubMedCrossRef
99.
Malhotra A, Buttrick P, Scheuer J: Effects of sex hormones on development of physiological and pathological cardiac hypertrophy in male and female rats. Am J Physiol. 1990, 259: H866-H871.PubMed
100.
Iafrati MD, Karas RH, Aronovitz M, et al: Estrogen inhibits the vascular injury response in estrogen receptor alpha-deficient mice. Nat Med. 1997, 3: 545-548., See [102]PubMedCrossRef
101.
Lindner V, Kim SK, Karas RH, et al: Increased expression of estrogen receptor-beta mRNA in male blood vessels after vascular injury. Circulation Res. 1998, 83: 224-229., See [102]PubMedCrossRef
102.
Karas RH, Hodgin JB, Kwoun M, et al: Estrogen inhibits the vascular injury response in estrogen receptor beta-deficient female mice. Proc Natl Acad Sci USA. 1999, 96: 15133-15136. 10.1073/pnas.96.26.15133., These three papers [100–102] form an important series of papers about the roles of the two estrogen receptors in the vessel wall. They are particularly interesting studies because we do not now have, but are in the process of obtaining, answers to this important questionPubMedPubMedCentralCrossRef
103.
McEwen BS, Alves SE: Estrogen actions in the central nervous system. Endocrine Rev. 1999, 20: 279-307. 10.1210/er.20.3.279.
104.
Simerly RB, Chang C, Muramatsu M, et al: Distribution of androgen and estrogen receptor mRNA-containing cells in the rat brain: an in situ hybridization study. J Comp Neurol. 1990, 294: 76-95.PubMedCrossRef
105.
Shughrue PJ, Lane MV, Merchenthaler I: Comparative distribution of estrogen receptor-α and -β mRNA in the rat central nervous system. J Comp Neurol. 1997, 388: 507-525. 10.1002/(SICI)1096-9861(19971201)388:4<507::AID-CNE1>3.0.CO;2-6.PubMedCrossRef
106.
Shughrue PJ, Lubahn DB, Negro-Vilar A, et al: Responses in the brain of estrogen receptor α-disrupted mice. Proc Natl Acad Sci USA. 1997, 94: 11008-11012. 10.1073/pnas.94.20.11008.PubMedPubMedCentralCrossRef
107.
Laflamme N, Nappi RE, Drolet G, et al: Expression and neuropeptidergic characterization of estrogen receptors (ERα and ERβ) throughout the rat brain: anatomical evidence of distinct roles of each subtype. J Neurobiol. 1998, 36: 357-378. 10.1002/(SICI)1097-4695(19980905)36:3<357::AID-NEU5>3.3.CO;2-U.PubMedCrossRef
108.
Kuiper GGJM, Shughrue PJ, Merchenthaler I, et al: The estrogen receptor β subtype: a novel mediator of estrogen action in neuroendocrine systems. Front Neuroendocrinol. 1998, 19: 253-286. 10.1006/frne.1998.0170.PubMedCrossRef
109.
Moffatt CA, Rissman EF, Shupnik MA, et al: Induction of progestin receptors by estradiol in the forebrain of estrogen receptor-β gene-disrupted mice. J Neurosci. 1998, 18: 9556-9563.PubMed
110.
Shughrue PJ, Lane MV, Merchenthaler I: Autoradiographic evidence for the binding of 125I-estrogen to estrogen receptor-β (ERβ) in the wild type and ERα-knockout (ERαKO) mouse brain [abstract 734.13]. Soc Neurosci Abstr. 1998, 24: 1849-
111.
Shughrue PJ, Lane MV, Merchenthaler I: Biologically active estrogen receptor-β: evidence from in vivo autoradiographic studies with estrogen receptor α-knockout mice. Endocrinology. 1999, 140: 2613-2620. 10.1210/en.140.6.2613.PubMed
112.
Couse JF, Korach KS: Estrogen receptor null mice: what have we learned and where will they lead us?. Endocrine Rev. 1999, 20: 358-417. 10.1210/er.20.3.358.CrossRef
113.
Mitchner NA, Garlick C, Ben-Jonathan N: Cellular distribution and gene regulation of estrogen receptors α and β in the rat pituitary gland. Endocrinology. 1998, 139: 3976-3983. 10.1210/en.139.9.3976.PubMed
Metadata
Title
Estrogen receptor transcription and transactivation Basic aspects of estrogen action
Authors
Stefan Nilsson
Jan-Åke Gustafsson
Publication date
01-10-2000
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 5/2000
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr81

Other articles of this Issue 5/2000

Breast Cancer Research 5/2000 Go to the issue

Review

Estrogen receptor transcription and transactivation Structure-function relationship in DNA- and ligand-binding domains of estrogen receptors

Research article

Polymorphic repeat in AIB1 does not alter breast cancer risk

Commentary

Nontransgenic models of breast cancer

Commentary

Role of BRCAgene dysfunction in breast and ovarian cancer predisposition

Review

Estrogen receptor transcription and transactivation Estrogen receptor knockout mice: what their phenotypes reveal about mechanisms of estrogen action

Commentary

Metastases: the glycan connection
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits